Covance

Covance, M2Gen to promote faster patient recruitment in biomarker-driven oncology trials

Tuesday, February 26, 2013 09:35 AM

Covance, a Princeton, N.J.-based provider of drug development services, has entered into an exclusive alliance and services agreement with M2Gen, a subsidiary of the Moffitt Cancer Center and developer of personalized cancer treatments.

More... »

Synteract appoints Kelson as CFO, Doren as vice president of biometrics

Wednesday, January 30, 2013 03:18 PM

Synteract, a full service CRO based in Carlsbad, Calif., has hired new executives to support customers on a global scale. Keith Kelson will serve as chief financial officer and member of its executive council, and Phil Doren has been appointed vice president of biometrics.

More... »

Covance launches five-year collaboration on early clinical research

Friday, January 18, 2013 01:23 PM

Global CRO Covance and the Royal Liverpool and Broadgreen University Hospitals NHS Trust have entered into a five-year exclusive agreement to work together in conducting early clinical trials at the Royal Liverpool University Hospital on behalf of biotechnology and pharmaceutical companies.

More... »

Covance receives SFDA GLP certification for early development facility

Wednesday, December 5, 2012 09:16 AM

Covance, a drug development services company, announced that its early development facility located in Shanghai, China, has received a Good Laboratory Practice (GLP) certificate from the State Food and Drug Administration (SFDA) of the People’s Republic of China.

More... »

GNS Healthcare, Covance to enable more efficient, cost-effective drug development

Friday, September 21, 2012 02:31 PM

GNS Healthcare, a Cambridge, Mass.-based healthcare data analytics company focused on enabling personalized medicine, has entered into a collaboration with global CRO Covance to develop novel data-driven models that will assist pharmaceutical companies in optimizing the efficiency and cost-effectiveness of drug development activities.

More... »

Covance U.K. sites receive Carbon Trust Standard accreditation

Monday, June 18, 2012 11:44 AM

Covance, a provider of drug development services based in Princeton, N.J., has received Carbon Trust Standard accreditation in the U.K. for its commitment to measuring, managing and reducing energy consumption and carbon emissions. 

More... »

Bayer and Covance form strategic partnership

Thursday, May 31, 2012 10:52 AM

Bayer HealthCare and Covance, a CRO based in Princeton, N.J., have established a long-term strategic partnership in the area of clinical drug development including R&D services related to phase II-IV clinical studies and central laboratory services.

More... »

Covance announces executive appointments

Friday, May 4, 2012 04:08 AM

Covance, a Princeton, N.J.-based provider of drug development services, has promoted Bill Klitgaard to corporate senior vice president and chief information officer, and Alison Cornell to corporate vice president and chief financial officer, effective May 8 upon approval by the board of directors.

More... »

Covance-BML lab to expand in Japan

Thursday, April 26, 2012 03:07 PM

CRO Covance of Princeton, N.J., and BML, a Japanese laboratory testing company, will expand the Covance-BML Clinical Trial Laboratory (CB Trial Lab) in Kawagoe City, Saitama Prefecture, to enhance the capacity and capabilities in the region. The companies, which opened the lab together in 2010 as part of a five-year agreement, will launch several new expansion-related services this month.

More... »

ACT Oncology names Julia Amo as COO

Wednesday, March 28, 2012 12:02 PM

ACT Oncology, a niche oncology service provider, has appointed Julia Amo, MBA, PMP, as chief operating officer.

More... »